2021.08.11
4B Technologies Ltd. ("4B Technologies") and Elixiron Immunotherapeutics (Hong Kong) Limited ("Elixiron") recently that 4B Technologies has obtained the exclusive rights to develop, manufacture and commercialize an innovative drug by Elixiron.
4B Technologies is an innovative biopharmaceutical company dedicated to the development and marketing of new drugs treating neurodegenerative diseases.
Elixiron is a well-known biopharmaceutical company focused on the development of innovative immunotherapeutic drugs.
JunHe assisted 4B Technologies in this acquisition and provided services such as conducting intellectual property due diligence in respect to whether the drug can be freely implemented, the status of Elixiron’s relevant patents and the extent of protection given. JunHe’s team also modified and negotiated the license agreement. Throughout this transaction, our team won high praise from our clients due to our high-quality, rigorous, efficient and professional legal service.
The leading partners of the project were Mr. ZHU, Jian (James J. Zhu, Ph.D.), Mr. ZHAO, Hao (Gerry) and WU, Yu (Sophia). Mr. CHEN, Zhiyao also provided valuable advice on litigation issues in the project.
